{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:39:01Z","timestamp":1775767141286,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/leu.2011.246","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T17:35:31Z","timestamp":1315589731000},"page":"443-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML"],"prefix":"10.1038","volume":"26","author":[{"given":"B Z","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D H","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"BFleu2011246_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0304-3835(96)04554-5","volume":"112","author":"LA Shamon","year":"1997","unstructured":"Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from tripterygium wilfordii. Cancer Lett 1997; 112: 113\u2013117.","journal-title":"Cancer Lett"},{"key":"BFleu2011246_CR2","first-page":"2666","volume":"8","author":"TM Kiviharju","year":"2002","unstructured":"Kiviharju TM, Lecane PS, Sellers RG, Peehl DM . Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8: 2666\u20132674.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011246_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood-2005-09-3898","volume":"108","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630\u2013637.","journal-title":"Blood"},{"key":"BFleu2011246_CR4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","volume":"8","author":"DH Mak","year":"2009","unstructured":"Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009; 8: 2509\u20132516.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011246_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0304-3835(98)00222-5","volume":"133","author":"T Tengchaisri","year":"1998","unstructured":"Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S . Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett 1998; 133: 169\u2013175.","journal-title":"Cancer Lett"},{"key":"BFleu2011246_CR6","doi-asserted-by":"publisher","first-page":"13451","DOI":"10.1074\/jbc.274.19.13451","volume":"274","author":"KY Lee","year":"1999","unstructured":"Lee KY, Chang W, Qiu D, Kao PN, Rosen GD . PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999; 274: 13451\u201313455.","journal-title":"J Biol Chem"},{"key":"BFleu2011246_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1074\/jbc.M009713200","volume":"276","author":"WT Chang","year":"2001","unstructured":"Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276: 2221\u20132227.","journal-title":"J Biol Chem"},{"key":"BFleu2011246_CR8","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1038\/sj.onc.1206842","volume":"22","author":"S Frese","year":"2003","unstructured":"Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC et al. PG490-mediated sensitization of lung cancer cells to Apo2L\/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003; 22: 5427\u20135435.","journal-title":"Oncogene"},{"key":"BFleu2011246_CR9","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1182\/blood-2007-05-091504","volume":"111","author":"BZ Carter","year":"2008","unstructured":"Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742\u20133750.","journal-title":"Blood"},{"key":"BFleu2011246_CR10","first-page":"65","volume":"2","author":"S Yang","year":"2003","unstructured":"Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2: 65\u201372.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011246_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/emm.2002.64","volume":"34","author":"KY Lee","year":"2002","unstructured":"Lee KY, Park JS, Jee YK, Rosen GD . Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 2002; 34: 462\u2013468.","journal-title":"Exp Mol Med"},{"key":"BFleu2011246_CR12","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.1074\/jbc.274.19.13443","volume":"274","author":"D Qiu","year":"1999","unstructured":"Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box\/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 13443\u201313450.","journal-title":"J Biol Chem"},{"key":"BFleu2011246_CR13","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1074\/jbc.M512044200","volume":"281","author":"SD Westerheide","year":"2006","unstructured":"Westerheide SD, Kawahara TL, Orton K, Morimoto RI . Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006; 281: 9616\u20139622.","journal-title":"J Biol Chem"},{"key":"BFleu2011246_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/1042819031000139710","volume":"45","author":"YJ Lou","year":"2004","unstructured":"Lou YJ, Jin J . Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004; 45: 373\u2013376.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2011246_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/j.1745-7254.2006.00415.x","volume":"27","author":"C Zhang","year":"2006","unstructured":"Zhang C, Cui GH, Liu F, Wu QL, Chen Y . Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1\/CXCR4 axis in vitro. Acta Pharmacol Sin 2006; 27: 1438\u20131446.","journal-title":"Acta Pharmacol Sin"},{"key":"BFleu2011246_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.canlet.2009.11.018","volume":"292","author":"J Pan","year":"2010","unstructured":"Pan J . RNA polymerase\u2014an important molecular target of triptolide in cancer cells. Cancer Lett 2010; 292: 149\u2013152.","journal-title":"Cancer Lett"},{"key":"BFleu2011246_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-09-0549","volume":"8","author":"S Vispe","year":"2009","unstructured":"Vispe S, DeVries L, Creancier L, Besse J, Breand S, Hobson DJ et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009; 8: 2780\u20132790.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011246_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchembio.522","volume":"7","author":"DV Titov","year":"2011","unstructured":"Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011; 7: 182\u2013188.","journal-title":"Nat Chem Biol"},{"key":"BFleu2011246_CR19","first-page":"1","volume":"31","author":"L Lu","year":"2011","unstructured":"Lu L, Kanwar J, Schmitt S, Cui QC, Zhang C, Zhao C et al. Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant \u2018thunder god vine\u2019. Anticancer Res 2011; 31: 1\u201310.","journal-title":"Anticancer Res"},{"key":"BFleu2011246_CR20","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1021\/ja00775a078","volume":"94","author":"SM Kupchan","year":"1972","unstructured":"Kupchan SM, Court WA, Dailey Jr RG, Gilmore CJ, Bryan RF . Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972; 94: 7194\u20137195.","journal-title":"J Am Chem Soc"},{"key":"BFleu2011246_CR21","first-page":"855","volume":"2","author":"JM Fidler","year":"2003","unstructured":"Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003; 2: 855\u2013862.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011246_CR22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ejca.2009.01.026","volume":"45","author":"JJ Kitzen","year":"2009","unstructured":"Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der BD, van DL et al. Phase i dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45: 1764\u20131772.","journal-title":"Eur J Cancer"},{"key":"BFleu2011246_CR23","unstructured":"Harousseau JLH, Dombret HD, Pigneux AP, Michallet MM, Brandely MB . Phase I study of F60008, a triptolide derivative, in patients with refractory or relapsing acute leukemias. 13th Congress of the European Hematology Association (EHA) 2008, Ref Type: Abstract."},{"key":"BFleu2011246_CR24","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1158\/0008-5472.CAN-06-3629","volume":"67","author":"X Ling","year":"2007","unstructured":"Ling X, Konopleva M, Zeng Z, Ruvolo VR, Stephens LC, Schober W et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007; 67: 4210\u20134218.","journal-title":"Cancer Res"},{"key":"BFleu2011246_CR25","first-page":"3603","volume":"62","author":"M Studeny","year":"2002","unstructured":"Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M . Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603\u20133608.","journal-title":"Cancer Res"},{"key":"BFleu2011246_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1084\/jem.182.5.1545","volume":"182","author":"S Martin","year":"1995","unstructured":"Martin S, Reutelingsperger C, McGahon A, Rader J, van Schie R, LaFace D et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and ABL. J Exp Med 1995; 182: 1545\u20131556.","journal-title":"J Exp Med"},{"key":"BFleu2011246_CR27","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","volume":"107","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak D, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al. Regulation of survivin expression through bcr-abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib responsive CML cells. Blood 2006; 107: 1555\u20131563.","journal-title":"Blood"},{"key":"BFleu2011246_CR28","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.4161\/cc.5.19.3255","volume":"5","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 2006; 5: 2223\u20132229.","journal-title":"Cell Cycle"},{"key":"BFleu2011246_CR29","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","volume":"98","author":"ML Guzman","year":"2001","unstructured":"Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301\u20132307.","journal-title":"Blood"},{"key":"BFleu2011246_CR30","first-page":"1340","volume":"11","author":"J Fidler","year":"2010","unstructured":"Fidler J, An J, Musser JH, Mak D, Carter BZ, Andreeff M . Preclinical development of triptolide derivative MRx102 as a therapeutic agent for acute myeloid leukemia. Blood 2010; 11: 1340\u20131341.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:51:30Z","timestamp":1648738290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFleu2011246"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.246","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]},"assertion":[{"value":"18 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMF is an employee of MyeloRx and all the other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}